Abstract Library

#3015 Biopsy Specimen Diagnosis in Pulmonary Carcinoids, A Shot in the Dark

Introduction: Pulmonary carcinoids (PCs) are rare well-differentiated neuroendocrine tumors, which can be separated into typical carcinoid (TC) and atypical carcinoid (AC). Advised treatment for local carcinoid disease is surgical resection using lobectomy, while parenchymal saving strategies such as sub-lobar or endobronchial resection might be considered for TC. In general, pre-operative diagnosis using a (transbronchial/transthoracic) biopsy sample is performed to demonstrate malignancy. However, TC and AC classification can solely be performed on surgical resection specimens, which may challenge pre-operative treatment decisions.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Moonen L

Authors: Moonen L, Derks J, Hermans B, Dingemans A, Speel E,

Keywords: pulmonary, neuroendocrine, carcinoid, biopsy, resection, diagnosis,

#1021 Recurrent Carcinoid Valvulopathy after Bioprosthetic Valve Surgery

Introduction: Carcinoid heart disease (CHD) typically affects right-sided cardiac structures causing leaflet thickening, retraction and valve dysfunction requiring surgery.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Zacks J, Canovas E, Lavine R, Warner R,

Keywords: valves, recurrent carcinoid disease, serotonin,

#678 Management of Patients with Neuroendocrine Tumors: Case Presentations Including Long-term, Open-label Pasireotide

Introduction: The somatostatin analog (SSA) pasireotide long-acting release (pasireotide LAR) is under investigation for the treatment of patients (pts) with NET and carcinoid disease refractory or resistant to available SSA.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Wolin E

Authors: Wolin E, Giannone V, Hermasillo Resendiz K,

Keywords: somatostatin analog, pasireotide, carcinoid syndrome,

#105 A pilot study using biochemical markers to predict acrcinoid heart disease in patients with carcinoid disease

Introduction: Carcinoid heart disease (CHD) affects up to 15-70% of patients with carcinoid disease. Recent ENETS guidelines recommend regular echocardiographic assessment to screen for CHD. Chromogranin A (CgA) is a peptide widely used to monitor carcinoid disease progression. Neurokinin A is a tachykinin which may be a more sensitive measure of carcinoid disease progression and prognosis. N-terminal pro Brain Naturetic Peptide is used as a screening tool for heart failure and recent results suggest utility in the diagnosis of CHD.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Wong C, Burgess M, Banks M, Ardill J, Poston G,

Keywords: carcinoid disease, chromogranin A, Neurokinin A, N-Terminal Barin Naturetic Peptide, carcinoid heart disease, echocardiography,

#104 Myocardial motion abnormalities in patients with carcinoid disease without overt carcinoid heart disease

Introduction: Cardiac abnormalities occur in 15-70% of patients with carcinoid disease, typified by fibrosis of the right-sided valves. Myocardial motion abnormalities in subjects without overt carcinoid heart disease have not been previously described. Tissue Doppler Imaging (TDI) allows quantative analysis of myocardial motion. We used this technique to investigate whether myocardial motion is reduced, suggesting fibrosis, in patients with carcinoid disease.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Wong C, Burgess M, Banks M, Poston G, Cuthbertson D,

Keywords: carcinoid heart disease, tissue doppler imaging, carcinoid syndrome, metastatic carcinoid disease, echocardiography,